A phase I and pharmacological study of topotecan infused over 30 minutes for five days in patients with refractory acute leukemia

Clinical Cancer Research

Volumn 2, Issue 12, 1996, Pages 1921-1930

  Rowinsky, Eric K ^a,c   Kaufmann, Scott H ^b   Baker, Sharyn D ^a,c   Miller, Carrole B ^a   Sartorius, Susan E ^a   Bowling, M Kathy ^a   Chen, Tian Ling ^d   Donehower, Ross C ^a   Gore, Steven D ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b MAYO CLINIC   (United States)

^c CTRC Institute for Drug Development   (United States)

^d Mayo Clinic ^*

Author keywords

[No Author keywords available]

Indexed keywords

TOPOTECAN;

ACUTE LEUKEMIA; ADULT; AGED; ANEMIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; FEVER; HUMAN; HYPERBILIRUBINEMIA; INTRAVENOUS DRUG ADMINISTRATION; MALE; MUCOSA INFLAMMATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RIGOR;

ACUTE DISEASE; ADULT; AGED; ANTINEOPLASTIC AGENTS; BONE MARROW; DNA TOPOISOMERASES, TYPE I; FEMALE; HUMANS; LEUKEMIA; MALE; MIDDLE AGED; MUCOUS MEMBRANE; NEOPLASM RECURRENCE, LOCAL; TOPOTECAN; TREATMENT OUTCOME;

EID: 0030470060     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Kingsbury, W. D., Boehm, J. C., Jakas, D. R , Holden, K. G., Hecht, S. M., Gallagher, G., Caranfa, M. J., McCabe, F L., Faucette, L. F., Johnson, R. K., and Hertzberg, R. P. Synthesis of water-soluble (aminoalkyl)camptothecin analogues: inhibition of topoisomerase I and antitumor activity. J. Med. Chem., 34: 98-107, 1991.
2. Slichenmyer, W. J., Rowinsky, E. K., Donehower, R. C., and Kaufmann, S. H. The current status of camptothecin analogues as antitumor agents. J. Natl. Cancer Inst., 85: 271-291, 1993.
3. Chen, A. Y., and Liu, L. F. DNA topoisomerases: essential enzymes and lethal targets. Annu Rev. Pharmacol. Toxicol., 34: 191-218, 1994.
4. Pommier, Y., Leteurtre, F., Fesen, M. R., Fujimori, A., Bertrand, R., Solary, E., Kohlhagen, G., and Kohn, K. W. Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors Cancer Invest., 12: 530-542, 1994.
5. Potmeisil, M. P. Camptothecins: from bench research to hospital wards. Cancer Res., 54: 1431-1439, 1994.
6. Froelich-Ammon, S. J., and Osheroff, N. Topoisomerase poisons: harnessing the dark side of enzyme mechanism. J. Biol. Chem., 270: 21429-21432, 1995.
7. Johnson, R. K., Hertzberg, R. P., Kingsbury, W. D., Boehm, J. C., Caranfa, M. J., Faucette, L. F., McCabe, F. L., and Holden, K G. Preclinical profile of SKF 104864, a water soluble analogue of camptothecin. Proceedings of the Sixth NCI-EORTC Symposium on New Drugs in Cancer Therapy, p. 301, 1989.
8. Houghton, P. J., Cheshire, P. J., Hallman, J. C., Bissery, M. C., Mathieu-Boue, A., and Houghton, J. A. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[piperidino]-1-piperidon)-carbonyl-oxy-campthotecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycampthothecin. Cancer Res., 53: 2823-2829, 1993.
9. Rowinsky, E., Grochow, L., Hendricks, C., Sartorius, S., Ettinger, D., McGuire, W., Forastiere, A., Hurowitz, L., Easter, V , and Donehower, R. Phase I and pharmacologic study of topotecan (SKF 104864), a novel topoisomerase I inhibitor. J. Clin. Oncol., 10: 647-656, 1992
10. van Warmerdam, L. J. C., Verweij, J., Schellens, J. H. M., Rosing, H., Davies, B. E., de Boer-Dennert, M., Maes, R. A. A., and Beijnen, J. H. Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks. Cancer Chemother. Pharmacol., 35: 237-245, 1995.
11. Saltz, L., Sirott, M., Young, C., Tong, W., Niedzwiecki, D., Tzy-Jyun, Y., Tao, Y., Trochanowski, B., Wright, P., Barbosa, K., Toomasi, F., and Kelsen, D. Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor. J. Natl. Cancer Inst., 85: 1499-1507, 1993.
12. Hochster, H., Liebes, L., Speyer, J., Sorich, J., Taubes, B., Oratz, R., Wernz, J., Chauchoua, A., Raphael, B., Vinci, R. Z., and Blum, R. H. Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen. J. Clin. Oncol., 12: 533-539, 1994.
13. Creemers, G. J., Bolis, G., Gore, M., Scarfone, G., Lacave, A. J., Guastalla, J. P., Despax, R., Favalli, G., Kreinberg, R., Van Belle, S., Hudson, I , Verweij, J., and Ten Bokkel Huinink, W. W. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. J. Clin. Oncol., in press, 1996.
14. Armstrong, D., Rowinsky, E., Donehower, R. C., Rosenshein, N. B., Walczak, J., and McGuire, W. Phase II study of topotecan as salvage therapy in epithelial ovarian cancer. Proc. Am. Soc. Clin. Oncol, 14: 275, 1995.
15. Carmichael, J., Gordon, A., Malfetano, J., Gore, M., Spaczynski, M., Davidson, N., Savage, J., Clarke-Pearson, D., Hudson, I., and Broom, C. Ten Bokkel Huinink, W. Topotecan, a new active drug, versus paclitaxel in advanced ovarian carcinoma: International Topotecan Study Group Trial. Proc. Am. Soc. Clin Oncol., 15: 283, 1996.
16. Kudelka, A. P., Tresukosol, D., Edwards, C. L., Freedman, R. S., Levenback, C., Chantarawiroj, P. Gonzalez de Leon, C., Kim, E. E., Madden, T., Wallin, B., Hord, M., Verschraegen, C., Raber, M., and Kavanagh, J. J. Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J. Clin. Oncol., 14: 1552-1557, 1996.
17. Eisenhauer, E. A., Wainman, G., Boos, G., Macdonald, V., and Bramwell, V. Phase II trials of topotecan in patients with malignant glioma and soft tissue sarcoma. Proc. Am. Soc. Clin. Oncol., 13: 175, 1994
18. Robert, F., Wheeler, R. H., Molthrop, D. C. Greene, P., and Chen, S. Phase II study of topotecan in advanced head and neck cancer: identification of an active new agent. Proc. Am. Soc. Clin. Oncol., 13: 281, 1994.
19. Perez-Soler, R., Fossella, F. V., Glisson, B. S., Lee, J. S., Murphy, W. K., Shin, D. M., Kemp, B. L., Lee, J. J., Kane, J., Robinson, R. A., Lippman, S. M., Kurie, J. M., Huber, M. H., Raber, M. N., and Hong, W. K. Phase II trial of topotecan in patients with advanced non-small cell lung cancer previously untreated with chemotherapy. J. Clin. Oncol., 14: 503-513, 1996.
20. Chang, A. Y., Garrow, G., Boros, L., Asbury, R., Pandya, K., and Keng, P. Clinical and laboratory studies of topotecan in breast cancer. Proc. Am. Soc. Clin. Oncol., 14: 105, 1995.
21. Ardizzoni, A., Hansen, H., Dombernowsky, P., Postmus, P., Buitenhuis, M., Wanders, J., McDonald, M., and Giaccone, G Phase II study of topotecan in pretreated small cell lung cancer. Proc. Am. Soc. Clin. Oncol., 13: 336, 1994.
22. Noda, K , Sasaki, H., Yamamoto, T., Yamamoto, R., Nishimura, R., Sugiyama, T., and Nakajima, H. Phase II trial of topotecan for cervical cancer of the uterus. Proc. Am. Soc. Clin. Oncol., 15: 280, 1996.
23. Kantajarian, H. M., Beran, M., Ellis, A., Zwelling, L., O'Brian, S., Cazenave, L., Koller, C., Rios, M. B., Plunkett, W., Keating, M. J., and Estey, E. H. Phase I study of topotecan, a new topoisomerase I inhibitor. in patients with refractory or relapsed leukemia. Blood, 81: 1146-1151, 1993.
24. Rowinsky, E. K., Adjei, A., Donehower, R. C., Gore, S., Jones, R. J., Burke, P. J., Cheng, Y-C., Grochow, L. B., and Kaufmann, S. H. A phase I and pharmacodynamic study of the topoisomerase I inhibitor topotecan in patients with refractory acute leukemia. J. Clin. Oncol., 12: 2193-2203, 1994.
25. Rowinsky, E. K., Grochow, L. B., Sartorius, S. E., Bowling, M. K., Kaufmann, S. H., Peereboom, D., and Donehower, R. C. A phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor. J. Clin. Oncol., 14: 1224-1235, 1996.
26. Division of Cancer Treatment, National Cancer Institute. Guidelines for Reporting of Adverse Drug Reactions. Bethesda, MD, 1988.
27. Cheson, B. D., Cassileth, P. A., Head, D. R., Schiffer, C. A., Bennett, J. M., Bloomfield, C. D., Brunning, R., Gale, R. P., Grever, M. R., Keating, M. J., Sawitsky, A., Stass, S., Weinstein, H., and Woods, W. G. Report on the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin. Oncol., 8: 813-819, 1990.
28. D'Argenio, D. Z., and Schumitzky, A. ADAPT II user's guide. University of Southern California, Biomedical Simulations Resource. Los Angeles, CA, 1990.
29. Peck, C. C., Beal, S. L., Sheiner, L. B., and Nichols, A. I. Extended least squares nonlinear regression: a possible solution to the choice of weights problem in analysis of individual data. J. Pharmacokinet. Biopharm., 12: 545-558, 1984.
30. Chang, J. Y., Dethlefsen, L A., Barley, L. R., Zhou, B. S., and Cheng, Y-C. Characterization of camptothecin-resistant Chinese hamster lung cells. Biochem. Pharmacol., 43: 2443-2452, 1992.
31. Boege, F., Andersen, A., Jensen, S., Zeidler, R., and Kreipe, H. Proliferation-associated nuclear antigen Ki-S1 is identical with topoisomerase II α. Am. J. Pathol., 146: 1302-1308, 1995.
32. Lamarre, D., Talbot, B., de Murcia, G., Laplante, C., Leduc, Y., Mazen, A., and Poirier, G. G. Structural and functional analysis of poly(ADP-ribose) polymerase: an immunological study. Biochim. Biophys. Acta, 950: 147-160, 1988.
33. Kaufmann, S. H., Karp, J. E., Jones, R. J., Miller, C. B., Schneider, E., Zwelling, L. A., Cowan, K., Wendel, K., and Burke, P. J. Topoisomerase II levels and drug sensitivity in adult acute myelogenous leukemia. Blood, 83: 517-530, 1994.
34. Fields, A. P., Kaufmann, S. H., and Shaper, J. H. Analysis of the internal nuclear matrix: oligomers of a 38 kD nucleolar polypeptide stabilized by disulfide bonds. Exp. Cell Res., 164: 139-153, 1986.
35. Kaufmann, S. H., McLaughlin, S. J., Kastan, M., Liu, L. F., Karp, J. E., and Burke, P. J. Topoisomerase II. Levels during granulocytic maturation in vitro and in vivo. Cancer Res., 51: 3534-3543, 1991.
36. Kaufmann, S. H., and Svingen, P. A. Immunoblot analysis and band depletion. In: M-A. Bjornsti and N. Osheroff (eds.), Protocols for DNA Topoisomerases. I. DNA Topology and Enzyme Purification. Totowa, NJ: Humana Press, in press, 1996.
37. Geller, R. B., Burke. P. J., Karp, J. E., Humphrey, R. L , Braine, H. G., Tucker, R. W., Fox, M. G., Zahurak, M. G., Morrell, L., Hall, K. L., and Piantadosi, S. A two-step timed sequential treatment for acute myelocytic leukemia. Blood, 74: 1499-1508, 1989.
38. Bravo, R., Frank, R., Blundell, P. A., and Macdonald-Bravo, H. Cyclin/PCNA is the auxiliary protein of DNA polymerase-δ. Nature (Lond.), 326: 515-518, 1987.
39. Prelich, G., Tan, C. K., Kostura, M., Mathew, M. B., So, A. G., Downey, K. M., and Stillman, B. Functional identity of proliferating cell nuclear antigen and a DNA polymerase-δ auxiliary protein. Nature (Lond.), 326: 517-520, 1987.
40. Feuerstein, N., Spiegel, S., and Mond, J. J. The nuclear matrix protein, numatrin (B23), is associated with growth factor-induced mitogenesis in Swiss 3T3 fibroblasts and with T lymphocyte proliferation stimulated by lectins and anti-T cell receptor antibody. J. Cell Biol., 107: 1629-1642, 1988.
41. Yamanaka, H., Willis, E. H., Penning, C. A., Peebles, C. L., Tan, E. M., and Carson, D. A. Human autoantibodies to poly(adenosine diphosphate-ribose) polymerase. J. Clin. Invest., 80: 900-904, 1987.
42. Tan, K. B., Mattern, M. R., Eng, W. K., McCabe, F. L., and Johnson, R. K. Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors. J. Natl. Cancer Inst., 81: 1732-1735, 1989.
43. Sugimoto, Y., Tsukahara, S., Ohara, T., Liu, L. F., and Tsuruo, T. Elevated expression of DNA topoisomerase II in camptothecin-resistant human tumor cell lines. Cancer Res., 50: 7962-7965, 1990.
44. Wall, J. G., Burris, H. A., Von Hoff, D D., Rodriquez, G., Kneuper-Hall, R., Shaffer, D., O'Rourke, T., Brown, T., Weiss, G., Clark, G., McVea, S., Brown, J., Johnson, R., Freiedman, C., Smith, B., Mann, W. S., and Kuhn, J. A phase I and clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SKF 104864) given as an intravenous bolus every 21 days. Anticancer Drugs, 3: 337-345, 1992.
45. Burris, H. A., Kuhn, J., Wall, J., Eckardt, J., Rodriguez, G., Johnson, R., Weiss, G., Shaffer, D., and Von Hoff, D. Early clinical trials of topotecan, a new topoisomerase I inhibitor. In: Proceedings of the Seventh NCI-EORTC Symposium on New Drugs in Cancer Therapy, p 118. Amsterdam, 1992.
46. Abigerges, D., Charbot, G., Armand, J-P, Herait, P., Gouyette, A., and Gandia, D. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J. Clin. Oncol., 13: 210-221, 1995.
47. Rowinsky, E. K., Grochow, L. B., Ettinger, D. S., Sartorius, S. E., Lubejko, B. J., Chen, T-L., Rock, M , and Donehower, R. C. Phase I and pharmacologic study of the novel topoisomerase I inhibitor CPT-11 administered as a 90 minute infusion every 3 weeks. Cancer Res., 54: 427-436, 1994.
48. Kaufmann, S. H., Charron, M., Burke, P. J., and Karp, J. E. Changes in topoisomerase I levels and subnuclear localization during myeloid maturation in vitro and in vivo. Cancer Res., 55: 1255-1260, 1995.